A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

J2K-MC-JZKA -

The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
What the trial is testing?
Could I receive a Placebo?
No
Enrollment Goal
5
Trial Dates
Nov 28, 2019 - Oct 30, 2020
How long will I be in the trial?
Your participation in this trial could last up to 24 months, depending on your cancer type and how you and your tumor respond.
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.